Long-term safety of finerenone in children and young adults with heart failure
Treatments studied
Part of Heart & circulation clinical trials.
This study tests the long-term safety of the drug finerenone when taken alongside standard heart failure treatments in children and young adults with weakened heart pumping function (left ventricular systolic dysfunction). It includes both children already in a related study and new infants under 6 months old.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have heart failure with a weakened left heart pump (left ventricular systolic dysfunction).
- For new infants under 6 months: A heart test (echocardiogram) shows a pumping strength of 50% or less.
- For new infants under 6 months: A blood test shows high NT-proBNP (a heart strain marker).
- New infants under 6 months must weigh at least 3 kg (about 6.6 pounds).
- No use of certain heart medications (spironolactone or eplerenone) within the last 30 days.
- No serious heart rhythm problems, need for a breathing machine, or IV heart support in the last 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called finerenone (a pill) to see if it helps children with heart failure who have a weak pumping heart. It compares finerenone to a placebo (a pill with no medicine) while both groups continue their usual heart treatments.
This trial studies how safely finerenone works over 18 months in children and young adults with chronic kidney disease who also take an ACE inhibitor or ARB. It aims to better understand long-term side effects when used together with standard kidney blood-pressure medicines.
This trial tests a medication called finerenone to see if it helps people hospitalized for heart failure live longer and have fewer heart-related problems. It may be an option for those with a certain type of heart failure where the heart's pumping strength is mildly reduced or normal.
This study tests whether a medication called finerenone can reduce scarring in the heart and improve heart function in people with heart failure who have ejection fractions of 40% or higher. You may be eligible if you've recently had heart failure symptoms requiring emergency care or medication changes.
This trial tests how safe and effective finerenone is for adults with chronic heart failure. It includes people whose heart pumps blood with at least 40% efficiency.
This observational study tracks how well finerenone (a kidney-protective medication) works in adults with type 2 diabetes and chronic kidney disease in Spain. Researchers will measure changes in kidney function and disease risk over time to better understand the medication's real-world benefits.
Hear when a new Left Ventricular Systolic Dysfunction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.